04/21/2016
New Genetic Test Helps To Select Best Medicines For Prostate Cancer Treatment And Identifies Hereditary Cancer Genes
Like self-driving cars, precision medicine for prostate cancer is no promise of the distant future -- with the efforts of Prostate Cancer Foundation (PCF)-funded researchers and others, the prototypes have arrived. The first major precision medicine studies were huge -- utilizing "whole exome" sequencing, in which every gene expressed by... Read More
06/02/2015
THE DISCOVERY OF NEW MOLECULAR MECHANISMS THAT MAY LINK OBESITY AND HIGH RISK PROSTATE CANCER
What this means for patients: Obesity is a known risk factor for prostate cancer, but the reasons for this remain unknown. This study identifies expression of chromatin remodeling genes as a likely mechanism linking these processes, and may lead to the development of therapies for obesity-related prostate cancer. June 2,... Read More
05/26/2015
The PARP-inhibitor Olaparib may be the first precision medicine therapy to reach prostate cancer patients
What this means for patients: A Phase II clinical trial found that up to one-third of metastatic prostate cancer patients have mutations in genes that control DNA repair in their tumors, causing them to selectively respond to treatment with olaparib. This therapy was recently approved for ovarian cancer patients who... Read More
05/21/2015
The Prostate Cancer Foundation-International Prostate Cancer Dream Team Demonstrates The Value Of Cancer Precision Medicine Strategies
What this means for patients: The Prostate Cancer Foundation (PCF)-sponsored International Prostate Cancer Dream Team has released results from a landmark study that uses gene sequencing technologies to identify the mutations present in tumors from individual prostate cancer patients. These results can be used to match each patient with medicines... Read More
07/01/2014
Making Science Real: Scientists moving forward in addressing research integrity; learning from past
Poor scientific reproducibility is a product of poor reagents, sloppiness, selective publishing of data, and on occasion – outright fraud. Drug development will continue to fail if results from published studies cannot be relied upon. How are scientists working to right these wrongs? July 2, 2014 -- Scientific fraud makes... Read More
06/05/2014
How the immune system can be harnessed to kill cancer
Understanding and improving on immunotherapies was a major focus at the 2014 AACR Annual Meeting. New studies are clarifying the reasons that immunotherapies have failed in some cancer types, and are revealing ways that the powerful potential of immunotherapies can be harnessed to improve the treatment of all cancer patients.... Read More
05/29/2014
Advances in Prostate Cancer Research from the 2014 AACR Annual Meeting
At the 2014 AACR Annual Meeting held in San Diego, CA this spring, Prostate Cancer Foundation-funded investigators discussed recent progress and exciting new studies regarding prostate cancer biology and treatment. May 29, 2014 -- Here, we highlight some of the most important research that was presented, including novel ways to... Read More
05/13/2014
Finding Cancer Solutions, One Cell at a Time
Hot new technologies and methods are making leaps forward in studying individual cancer cells—which will help prevent drug resistance to therapy and identify new drug targets. May 14, 2014 -- At the 2014 American Association for Cancer Research (AACR) Annual Meeting in San Diego held in April, a session titled... Read More
04/14/2014
EXPRESSIVE WRITING IMPROVES QUALITY OF LIFE FOR CANCER PATIENTS
April 14, 2014 -- Putting pen to paper, or fingers to keyboard, and pouring out inner thoughts seems to improve several quality of life aspects for cancer patients, according to a recent study published in the Journal of Clinical Oncology. In the study, 277 recently diagnosed renal carcinoma patients were... Read More
03/30/2014
PCF researchers discover molecular crosstalk that prostate cancer cells use to survive radiation therapy; Plan Steps to Halt that “Conversation”
Prostate Cancer Foundation-funded researchers published two studies this fall that help explain why androgen deprivation therapy improves survival when given with radiation therapy; ability to repair broken DNA implicated. Findings may predict which men are most likely to benefit from combination therapy, and could lead to novel treatments for advanced... Read More